No Opioids, No Addiction: FDA Approves First New Type of Painkiller in Decades
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
Hosted on MSN22m
Non-Opioid Pain Medication Journavx Gets FDA Approval
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
FDA approves painkiller said to thwart addiction
Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years ...
C&EN53m
FDA approves new nonopioid pain medication, hailed a 'triumph'
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.
The San Joaquin Valley Sun1h
Painkiller designed without risk of addiction approved by FDA
The U.S. Food and Drug Administration (FDA) has approved a new pain pill called Journavx, designed to mitigate the risks of addiction and overdose associated with opioid medications like Vicodin and ...
aha.org1h
FDA approves first-in-class non-opioid painkiller
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Healio2h
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
KIDY2h
FDA approves Journavx, the first new painkiller in over two decades
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
FDA approves suzetrigine, the first new painkiller since 1998
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998.
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.